Is MDA a Buy? What to Consider in 2026

Short answer

The bull case for MDA (MDA) rests on Satellite constellation buildout: MDA's largest segment builds software-defined satellites (MDA Aurora) and payloads for low-Earth-orbit and other constellations, and it opened a Montreal factory capable of up to 400 satellites per year. Revenue (2025) is ~CA$1.6 billion (up ~51% YoY). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: MDA's revenue is concentrated in a handful of large, lumpy programs, so a delay, cancellation, or schedule slip (as seen when Telesat Lightspeed's in-service target moved into 2028 on a supplier chip issue) can move results materially. Whether MDA is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

MDA Space Ltd. (NYSE: MDA; TSX: MDA) is a Canadian space-technology company that builds and operates hardware and systems across the space economy. It runs three business areas: Satellite Systems (software-defined satellites under the MDA Aurora product line, plus payloads and antennas for low-, medium-, and geosynchronous-orbit constellations), Robotics and Space Operations (the Canadarm robotic arms, including the Canadarm3 program for NASA's lunar Gateway), and Geointelligence (Earth-observation imagery and analytics, anchored by the MDA Chorus radar constellation expected to launch in late 2026). Headquartered near Toronto with major operations in Montreal, MDA has decades of spaceflight heritage and supplies both commercial constellation customers and government and defense agencies. MDA completed a roughly US$300 million IPO and NYSE dual-listing in March 2026, adding a US market alongside its long-standing Toronto listing. The investment picture is a profitable, growing contractor riding a wave of satellite-constellation and defense spending: revenue jumped in 2025 and again in early 2026 as it converts a multi-billion-dollar backlog into sales on programs like Telesat Lightspeed, Globalstar's next-generation network, and Canadarm3. The stock trades at a premium multiple that prices in continued growth, so it is sensitive to program schedules, customer funding, and backlog conversion.

What's the case for buying MDA?

1. Satellite constellation buildout.

MDA's largest segment builds software-defined satellites (MDA Aurora) and payloads for low-Earth-orbit and other constellations, and it opened a Montreal factory capable of up to 400 satellites per year. Major programs including Telesat Lightspeed and Globalstar's next-generation network drove Satellite Systems revenue up roughly 41 percent year over year in early 2026, making constellation demand the primary growth engine.

2. Robotics and Canadarm3.

MDA's robotics heritage spans the Space Shuttle and International Space Station Canadarms, and it is building Canadarm3 for NASA's lunar Gateway. This is a differentiated, hard-to-replicate franchise that provides multi-year government-backed revenue and positions MDA for future in-orbit servicing and lunar and Mars surface operations.

3. Geointelligence and MDA Chorus.

The Geointelligence unit sells Earth-observation imagery and analytics for national security, maritime surveillance, and climate monitoring. Its next-generation MDA Chorus radar constellation, expected to launch in late 2026, is a growth catalyst that could expand recurring data revenue if deployed on schedule.

4. Backlog and defense tailwinds.

MDA reported a backlog of roughly CA$3.7 billion and a stated pipeline near CA$40 billion in early 2026, giving multi-year revenue visibility. Rising global defense and space spending, plus demand for resilient satellite communications and imagery, support continued bidding for large commercial and government contracts.

What are the risks to MDA?

MDA's revenue is concentrated in a handful of large, lumpy programs, so a delay, cancellation, or schedule slip (as seen when Telesat Lightspeed's in-service target moved into 2028 on a supplier chip issue) can move results materially. It carries execution and fixed-price contract risk on complex hardware, and free cash flow can be neutral to negative in heavy investment years due to factory expansion and chip development capex. The company reports in Canadian dollars and depends on government funding cycles and export approvals, adding currency and policy exposure. Competition from larger primes and vertically integrated players like SpaceX pressures pricing and contract wins. As a premium-multiple growth name, the stock is sensitive to sentiment, backlog conversion, and quarter-to-quarter program timing.

How is MDA valued? (as of JULY 2026)

Price

$38.67

Market cap

$5.37B

P/E (TTM)

70.31

Forward P/E

32.92

Price / book

5.01

52-week range

$23.23 to $49.37

Snapshot for MDA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (2025): ~CA$1.6 billion (up ~51% YoY)
Revenue (Q1 2026): ~CA$464 million (up ~32% YoY)
Adjusted EBITDA (Q1 2026): ~CA$91 million
2026 revenue guidance: ~CA$1.7 to 1.9 billion
Backlog / pipeline: ~CA$3.7B backlog, ~CA$40B pipeline
Market cap: ~US$5.5 billion

MDA is profitable and growing, with early-2026 revenue up about 32 percent year over year and full-year 2026 guidance for roughly CA$1.7 to 1.9 billion in revenue and CA$320 to 370 million in adjusted EBITDA (an 18 to 20 percent margin). It trades at a premium earnings multiple that prices in continued backlog conversion, and free cash flow is guided neutral to negative as it funds factory expansion and chip development. Figures are approximate and reported in Canadian dollars; the NYSE market cap is in US dollars.

How do you decide if MDA is a buy?

Rather than asking whether MDA is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold MDA indirectly through an index or sector ETF before adding more.

For the full picture, see the MDA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MDA against your real portfolio and see your actual exposure before deciding.

The bottom line on MDA

The bottom line: MDA's story right now is Satellite constellation buildout, with revenue (2025) at ~CA$1.6 billion (up ~51% YoY). If you believe that narrative continues, the call is about sizing MDA sensibly and checking overlap with what you own; if you doubt it (the risk: mDA's revenue is concentrated in a handful of large, lumpy programs, so a delay, cancellation, or schedule slip (as seen when Telesat Lightspeed's in-service target moved into 2028 on a supplier chip issue) can move results materially.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around MDA with Walnut

Use MDA as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is MDA a good stock to buy right now?

The case for MDA right now is Satellite constellation buildout, with revenue (2025) at ~CA$1.6 billion (up ~51% YoY). If you believe that thesis holds, MDA is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is mDA's revenue is concentrated in a handful of large, lumpy programs, so a delay, cancellation, or schedule slip (as seen when Telesat Lightspeed's in-service target moved into 2028 on a supplier chip issue) can move results materially. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does MDA do?

MDA Space Ltd.

What are the main risks of MDA?

What is MDA's ticker symbol and where is it listed?

MDA, for MDA Space Ltd. It dual-listed on the New York Stock Exchange (NYSE: MDA) in March 2026 and also trades in Canada on the Toronto Stock Exchange (TSX: MDA). It is available at major US brokerages and trades during US market hours.

Is MDA the same as the Canadian MDA Space, or a different company?

They are the same company. MDA Space Ltd. is a Canadian space-technology firm headquartered near Toronto that long traded on the TSX and added a NYSE listing in March 2026 through a roughly US$300 million US IPO. Both listings use the ticker MDA.

What does MDA Space do?

MDA builds space hardware and systems across three areas: Satellite Systems (software-defined satellites and payloads for constellations), Robotics and Space Operations (the Canadarm arms, including Canadarm3 for NASA's lunar Gateway), and Geointelligence (Earth-observation imagery and analytics, led by the MDA Chorus radar constellation).

Is MDA Space profitable?

Yes. Unlike many earlier-stage space stocks, MDA is profitable and reports positive adjusted EBITDA and adjusted net income, which grew about 32 percent year over year in early 2026. Free cash flow can be neutral to negative in heavy investment years due to factory and chip-development capex.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MDA; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.